Recurrent moderate‐risk mutations in Finnish breast and ovarian cancer patients

Gene-panel testing of breast and ovarian cancer patients identifies a recurrent RAD51C duplication

(2018) L.M. Pelttari et al.   CLINICAL GENETICS

Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women

(2018) Ranjit Manchanda et al.   JNCI-Journal of the National Cancer Institute

OUP accepted manuscript

(2018)   JNCI-Journal of the National Cancer Institute

Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women

(2018) Ranjit Manchanda et al.   JNCI-Journal of the National Cancer Institute

OUP accepted manuscript

(2018)   JNCI-Journal of the National Cancer Institute

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Potentially pathogenic germline CHEK2 c.319+2T>A among multiple early-onset cancer families

(2017) Mev Dominguez-Valentin et al.   Familial Cancer

Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls

(2017) Jenna Lilyquist et al.   GYNECOLOGIC ONCOLOGY

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

(2017) Karoline B. Kuchenbaecker et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Rare, protein-truncating variants in ATM , CHEK2 and PALB2 , but not XRCC2 , are associated with increased breast cancer risks

(2017) Brennan Decker et al.   JOURNAL OF MEDICAL GENETICS

Association analysis identifies 65 new breast cancer risk loci

(2017) Kyriaki Michailidou et al.   NATURE

Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene

(2017) Ed Dicks et al.   Oncotarget

Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer

(2017) Fergus J. Couch et al.   JAMA Oncology

Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer

(2017) Guido Neidhardt et al.   JAMA Oncology

Genetic modifiers of CHEK2*1100delC-associated breast cancer risk

(2016) Taru A. Muranen et al.   GENETICS IN MEDICINE

Age- and Tumor Subtype–Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers

(2016) Marjanka K. Schmidt et al.   JOURNAL OF CLINICAL ONCOLOGY

Analysis of protein-coding genetic variation in 60,706 humans

(2016) Monkol Lek et al.   NATURE

Targeted Next-Generation Sequencing Identifies a Recurrent Mutation in MCPH1 Associating with Hereditary Breast Cancer Susceptibility

(2016) Tuomo Mantere et al.   PLoS Genetics

FANCMc.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor

(2015) Paolo Peterlongo et al.   HUMAN MOLECULAR GENETICS

Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants

(2015) Nasim Mavaddat et al.   JNCI-Journal of the National Cancer Institute

Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk

(2015) Douglas F. Easton et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants

(2015) Nasim Mavaddat et al.   JNCI-Journal of the National Cancer Institute

Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations

(2014) Anna P. Sokolenko et al.   BREAST CANCER RESEARCH AND TREATMENT

Breast-Cancer Risk in Families with Mutations in PALB2

(2014) Antonis C. Antoniou et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer

(2014) Johanna I. Kiiski et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Distribution and Medical Impact of Loss-of-Function Variants in the Finnish Founder Population

(2014) Elaine T. Lim et al.   PLoS Genetics

CHEK2*1100delC Heterozygosity in Women With Breast Cancer Associated With Early Death, Breast Cancer–Specific Death, and Increased Risk of a Second Breast Cancer

(2012) Maren Weischer et al.   JOURNAL OF CLINICAL ONCOLOGY

A Finnish founder mutation inRAD51D: analysis in breast, ovarian, prostate, and colorectal cancer: Table 1

(2012) Liisa M Pelttari et al.   JOURNAL OF MEDICAL GENETICS

Germline RAD51C mutations confer susceptibility to ovarian cancer

(2012) Chey Loveday et al.   NATURE GENETICS

Gene–gene interactions in breast cancer susceptibility

(2011) Clare Turnbull et al.   HUMAN MOLECULAR GENETICS

RAD51C is a susceptibility gene for ovarian cancer

(2011) Liisa M. Pelttari et al.   HUMAN MOLECULAR GENETICS

Risk of Breast Cancer in Women With a CHEK2 Mutation With and Without a Family History of Breast Cancer

(2011) Cezary Cybulski et al.   JOURNAL OF CLINICAL ONCOLOGY

Germline mutations in RAD51D confer susceptibility to ovarian cancer

(2011) Chey Loveday et al.   NATURE GENETICS

Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction

(2010) A. C. Antoniou et al.   CANCER RESEARCH

Rare, Evolutionarily Unlikely Missense Substitutions in ATM Confer Increased Risk of Breast Cancer

(2009) Sean V. Tavtigian et al.   AMERICAN JOURNAL OF HUMAN GENETICS

The Breast Cancer Susceptibility Mutation PALB2 1592delT Is Associated with an Aggressive Tumor Phenotype

(2009) T. Heikkinen et al.   CLINICAL CANCER RESEARCH

CHEK2*1100delC Genotyping for Clinical Assessment of Breast Cancer Risk: Meta-Analyses of 26,000 Patient Cases and 27,000 Controls

(2008) Maren Weischer et al.   JOURNAL OF CLINICAL ONCOLOGY

NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer

(2008) Rainer Fagerholm et al.   NATURE GENETICS